PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 79 filers reported holding PRELUDE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,094,820 | -61.0% | 287,354 | -51.5% | 0.00% | – |
Q1 2024 | $2,808,020 | +10.0% | 592,410 | -0.9% | 0.00% | – |
Q4 2023 | $2,551,720 | +237.8% | 597,592 | +144.4% | 0.00% | – |
Q3 2023 | $755,411 | -14.1% | 244,470 | +25.2% | 0.00% | – |
Q2 2023 | $878,968 | +8.9% | 195,326 | +37.9% | 0.00% | – |
Q1 2023 | $807,474 | +48.6% | 141,662 | +57.5% | 0.00% | – |
Q4 2022 | $543,291 | -53.8% | 89,949 | -49.4% | 0.00% | – |
Q3 2022 | $1,175,000 | -53.2% | 177,788 | -63.0% | 0.00% | – |
Q2 2022 | $2,510,000 | -33.4% | 480,788 | -12.0% | 0.00% | -100.0% |
Q1 2022 | $3,770,000 | -64.2% | 546,475 | -35.4% | 0.00% | 0.0% |
Q4 2021 | $10,528,000 | -55.5% | 845,714 | +11.8% | 0.00% | -66.7% |
Q3 2021 | $23,650,000 | +525.2% | 756,787 | +472.6% | 0.00% | – |
Q2 2021 | $3,783,000 | +262.4% | 132,165 | +449.0% | 0.00% | – |
Q1 2021 | $1,044,000 | -46.2% | 24,074 | -11.3% | 0.00% | – |
Q4 2020 | $1,941,000 | +390.2% | 27,128 | +106.2% | 0.00% | – |
Q3 2020 | $396,000 | – | 13,155 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Orbimed Advisors | 10,039,691 | $66,362,000 | 1.23% |
Baker Brothers Advisors | 10,123,824 | $66,918,000 | 0.44% |
HHLR ADVISORS, LTD. | 583,333 | $3,856,000 | 0.10% |
CAXTON ASSOCIATES LP | 85,992 | $568,000 | 0.08% |
Virtus ETF Advisers LLC | 24,180 | $160,000 | 0.06% |
GSA CAPITAL PARTNERS LLP | 54,173 | $358,000 | 0.05% |
DENALI ADVISORS LLC | 8,200 | $54,000 | 0.03% |
PDT Partners, LLC | 12,641 | $84,000 | 0.01% |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,402,595 | $15,881,153,000 | 0.01% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 36,949 | $244,000 | 0.01% |